Navigation Links
Omeros Commences Initial Public Offering of Common Stock
Date:9/18/2009

oking statements." These statements include, but are not limited to, those regarding Omeros' proposed initial public offering and expectations regarding its clinical development activities and the clinical benefits of its product candidates. These forward-looking statements are based on the current intent and expectations of the management of Omeros. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Omeros' actual results and the timing and outcome of events may differ materially from those expressed in or implied by the forward-looking statements because of risks associated with Omeros' clinical development activities, regulatory oversight, intellectual property rights and other risks. Omeros undertakes no obligation to update any forward-looking or other statements in this press release, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Omeros Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery
2. Omeros Appoints New Vice President of Clinical Development
3. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
4. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
5. Omeros and BlueCrest Announce $20 Million Debt Facility
6. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
7. Omeros Appoints David A. Mann to its Board of Directors
8. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
9. Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes
10. Oramed Pharmaceuticals Commences Human Clinical Trials of an Oral GLP-1 Analog
11. PCI Biotech Commences Phase I/II Trials of Amphinex(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... , July 2, 2015 ... Bio-tech procurement company Amici Procurement has chosen Microsoft ... help it move to Office 365.      ... provides small to medium-sized companies in the bio-tech sector ... aspects of the purchasing cycle to help them obtain ...
(Date:7/1/2015)... ... July 01, 2015 , ... It is now possible to separate ... single photon emission computed tomography (SPECT) according to researchers from Amen Clinics, UCLA, ... 20,000 brain scans and is believed to be the largest brain imaging study ever, ...
(Date:7/1/2015)... ... ... The next-generation sequencing (NGS) clinical market is poised for huge growth as it ... reveals in its new report that the market drivers of this vibrant industry include ... better diagnostics as part of a molecular diagnostics trend. , The global market is ...
(Date:7/1/2015)... 1, 2015  Axovant Sciences Ltd. (NYSE:  AXON), ... treatment of dementia, today announced that the company ... at 5:45 p.m. EDT following its presentation of ... Conference 2015 (AAIC). The event ... Dr. Lawrence Friedhoff , Chief Development Officer, ...
Breaking Biology Technology:Biotech Procurement Company Moves to Office 365 with iomart 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 4NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3
... June 19 Canopus,BioPharma, Inc. (OTC: CBIA), has ... a tumor reducing agent and has also demonstrated ... both cisplatin and,cetuximab (Erbitux) in two mice lung ... Patrick Prendergast, stated, "We at,Canopus are encouraged with ...
... Neuftec,Limited, the proprietor of the original nano-particulate cerium ... against Oxonica Energy,Limited, a wholly owned subsidiary of ... the High Court of Justice, has commented on ... Dr Matthews,(CEO) on 19 June 2008., Dr ...
... features Asian biopharmaceutical industry information on ... ... 19 BioSpace, the world,s,leading online community for the bioscience ... pharmaceutical and,medical devices industries in Asia. AsiaBio(TM) features dynamic,informational Hotbed ...
Cached Biology Technology:CB1400, Patented by Canopus BioPharma, Prevents Tumor Growth and Enhances the Anti-Tumor Effects of Cisplatin and Cetuximab (Erbitux). 2Neuftec Responds to a Fundamental Inaccuracy in Oxonica PLC's Regulatory Announcement 2BioSpace Announces New Online Community for Asia 2
(Date:6/24/2015)... Biometry authentication provider KeyLemon today announced ... one face in. Logo - ... in, entering the expanding biometric authentication market in ... answer to the password problem. With advanced face ... KeyLemon, one face in allows users to securely ...
(Date:6/23/2015)... N.C. , June 23, 2015   ... today announced the results of a recent study ... accuracy on the wrist during activity. In a ... technology was compared along with the Apple Watch ... accurately measuring heart rate during activity. The study ...
(Date:6/18/2015)... , June 18, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market announces that ... featured segment on "Money on the Mark", scheduled to air ... June 20 th . The ... be from 7:00 to 8:00pm EST. NXT-ID, Inc.,s CEO ...
Breaking Biology News(10 mins):KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3
... identified a key gene mutation responsible for type 2 diabetes ... The study, which originated in Italy and was validated ... to a major drop in the body,s ability to make ... the cell to absorb sugar. This drop in insulin receptors ...
... The American Heart Association estimates 35 percent of adults in ... factors characterized by obesity and the simultaneous presence of heart ... lipids. In patients with metabolic syndrome, high blood pressure ... affects the organ,s ability to filter waste from the body. ...
... able to navigate to specific locations up to 50km away, ... Journal of Animal Ecology has found. Re-analysing tracking data ... as blacktip reef sharks swim in a pattern known as ... times hunt for prey or mates by using "directed walks", ...
Cached Biology News:Type 2 diabetes linked to single gene mutation in 1 in 10 patients 2Study shows pine bark naturally improves kidney function in patients with metabolic syndrome 2Study shows pine bark naturally improves kidney function in patients with metabolic syndrome 3Shark tracking reveals impressive feats of navigation 2
Taq DNA Polymerase (cloned), 250 units. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzymes, Polymerases....
Ps-Aeruginosa (IgA) -Ab EIA Sample Size: 100 l...
...
...
Biology Products: